Circular RNA and Chemerin in Breast Cancer Patient

Breast Cancer Clinical Trial

Official title:

Circular RNA and Chemerin in Blood of Breast Cancer Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05771337
• Other study ID #: biomarkers in breast cancer
• Status: Not yet recruiting
• Start date: October 2023
• Est. completion date: December 2025

Study information

• Verified date: March 2023
• Source: Assiut University
• Contact: sandy nashat sorial
• Phone: 01200693648
• Email: sandybsbsa[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aimed to evaluate the role of serum chemerin as a biomarker of breast cancer.

and To investigate the diagnostic value of hsa_circ_0001785 (Circ-ELP3) and hsa_circ_100219 (Circ-FAF1) in serum samples of breast cancer patients to find out whether these circRNAs can utilize as a diagnostic and prognostic biomarker for human breast cancer assessment and make Correlation between serum chemerin levels , serum Circ-FAF1 , serum CircELP3 and classical tumor markers (CEA + CA15-3).

andTo elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.

Description:

Breast cancer is the most common cancer among women and despite advances in therapy over the past few decades, drug resistance, recurrence, metastasis and the heterogeneity of the cancer continue to be a problem in successful management of the diseases(Hong et al ,2019) .

Circular RNAs (CircRNAs) are single-stranded, covalently closed RNA molecules that are ubiquitous across species ranging from viruses to mammals(Zhou et al 3 .,2020). circRNAs can be divided into two categories including coding and noncoding circRNAs(Li et al., 2019) A new subtype of RNAs is circular RNAs, single-strand RNA molecules with less than 100 to more than 4,000 nucleotides (Lu et al., 2016) and a covalently closedloop structure. These molecules are produced through a backsplicing mechanism, in which the downstream 5'-end of the splice donor joins the upstream 3'-end splice acceptor and forms a product with a circular structure (wang et al., 2017).

Chemerin is a leukocyte chemoattractant widely expressed in many tissues and is known to recruit innate leukocytes.

Recently, more and more studies focus on the relationship between chemerin and cancers and found that chemerin acts an essential role in cancers.(Shin et al,2018) Chemerin expression is different depending on the tumor type (Zhang Y et al, 2013) the clinical significance of chemerin in breast cancer has been only reported by a very limited number of studies (EL Sagheer et al,2018).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: December 2025
• Est. primary completion date: October 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• histopathological diagnosis of breast cancer

Exclusion Criteria:

• history of other types of cancers

• history of HIV

• history of any therapeutic interventions in form of chemo or hormonal therapy before specimen collection

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Diagnostic Test:
• blood sample
blood sample

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (2)

Omid-Shafaat R, Moayeri H, Rahimi K, Menbari MN, Vahabzadeh Z, Hakhamaneshi MS, Nouri B, Ghaderi B, Abdi M. Serum Circ-FAF1/Circ-ELP3: A novel potential biomarker for breast cancer diagnosis. J Clin Lab Anal. 2021 Nov;35(11):e24008. doi: 10.1002/jcla.24008. Epub 2021 Sep 21. — View Citation

Song Y, Zhu X, Lin Z, Luo L, Wen D. The potential value of serum chemerin in patients with breast cancer. Sci Rep. 2021 Mar 22;11(1):6564. doi: 10.1038/s41598-021-85986-w. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	measure chemerin and Circular RNA in breast cancer patients	To elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.	2 years